

Perkins Coie Named Generic Hatch-Waxman Firm of the Year by LMG Life Sciences

SEATTLE (October 5, 2021)—Perkins Coie is pleased to announce that the firm has been recognized as [Hatch-Waxman Litigation Firm of the Year – Generic](#) by the LMG Life Sciences Americas Awards for the second year in a row. The recipients of the LMG Life Sciences Awards—an annual ranking of leading law firms and lawyers specializing in the industry—are determined through a research process involving practitioner submissions and interviews, client feedback, and independent research.

The firm's intellectual property (IP) attorneys represent clients across the full range of life sciences technologies, including biotechnology, pharmaceuticals (branded and generic), biologics, biosimilars, chemistry, diagnostics, medical devices, and digital health. Several IP attorneys have advanced degrees in molecular biology, chemistry, and biophysics, while others actively participate on boards of directors for various life sciences organizations, keeping them at the forefront of industry trends.

Perkins Coie is a leading international law firm that is known for providing high-value, strategic solutions and extraordinary client service on matters vital to our clients' success. With more than 1,200 lawyers in offices across the United States and Asia, we provide a full array of corporate, commercial litigation, intellectual property, and regulatory legal advice to a broad range of clients, including many of the world's most innovative companies and industry leaders as well as public and not-for-profit organizations.

Media Inquiries: Please email [Justin Cole](#), Head of Media Relations.

Explore more in

[Intellectual Property Law](#)

Media inquiries